DocGo A Aktie

DocGo missed expectations in the second quarter of 2026 with an adjusted loss per share of $0.16 (expectation $0.10) and revenue of $73.4 million (expectation $75.4 million). The company lowered its full-year adjusted EBITDA guidance to a loss of $17–22 million (previously -$5 to -$10 million). DocGo also announced the acquisition of Hicuity Health, to be funded largely by taking on about $52 million of debt and up to $50 million in new financing commitments, raising near-term balance-sheet concerns. Investor sentiment worsened and the stock fell sharply in premarket trading. » More on de.investing.com

DocGo reported an adjusted loss per share for Q2 2026 of $0.16 (expectation $0.10) and revenue of $73.4 million (expectation $75.4 million), after which the stock fell about 11% in after-hours trading. Management attributes the revenue decline to expired migrant contracts and, excluding those effects, reports organic growth; the medical transport segment reached a record level at $52.0 million. DocGo raised its 2026 adjusted EBITDA loss guidance to $17–22 million and confirmed an acquisition agreement for Hicuity Health to expand into virtual care. The company highlights sequential improvements and cost-reduction measures but warns of integration and margin risks and declining liquidity. » More on de.investing.com

DocGo rose in after-hours trading after second-quarter 2026 results were released after the close; the stock increased 2.4% to $0.727. The consensus had expected a loss of $0.15 per share (prior year: $0.21), which made the stock susceptible to positive reactions. The company filed with the SEC for an extension to submit its 10-Q, expects no material operational changes, and had previously raised its revenue guidance and extended a share buyback program. DocGo must meet Nasdaq listing requirements by January 25, 2027; analysts are divided, and investors are focusing on the management conference call at 5:00 p.m. ET. » More on de.investing.com